Article
Vildagliptin modulates the microbiota and induces an immunometabolic neuroprotective profile in type 2 diabetes
2025-05-30
Abstract excerpt
<title>Abstract</title> <p>Dipeptidyl peptidase 4 <bold>(</bold>DPP-4) inhibitors (DPP-4i) are widely used to treat Type 2 diabetes (T2D) and are known for their cardiovascular and renal safety profiles. Systematic reviews have also shown that DPP-4i are associated with reduced dementia risk via unknown mechanisms. To examine vildagliptin (DPP-4i) effects on the intestinal microbiota in T2D patients, plasma metab...
Topics
Open a Topic to create a Post that cites this publication.
- Clostridium difficile and Clostridium perfringens research
- Diet and metabolism studies
- Dysphagia Assessment and Management
- Gut microbiota and health
- Helicobacter pylori-related gastroenterology studies
- Metabolomics and Mass Spectrometry Studies
- Nutritional Studies and Diet
- Parkinson's Disease Mechanisms and Treatments
Identifiers and source
- Literature Corpus work
- ff58888b-07dd-5072-a90a-976648d17122
- DOI
- 10.21203/rs.3.rs-6596504/v1
